SYDNEY, Wednesday, 8 May 2013: Cellmid Limited (ASX:CDY) provides a copy of the presentation given by the CEO, Maria Halasz, in relation to the strategic acquisition of Advangen Inc. Japan.
Market opportunity for hair growth products
- Minoxidil sales: $300M annually (Newport Horizon)
- Advangen’s products are:
Clinically validated
No reported side effects (700,000 bottles sold in Japan in 5 years)
Suitable for men and women
98% of website users love the FGF-5 inhibitor products and would recommend it to their friends (Australian data).
To view Presentation please download PDF below:
